Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43506
UPID:
ADA20_HUMAN
Alternative names:
-
Alternative UPACC:
O43506; Q6GTZ1; Q9UKJ9
Background:
Disintegrin and metalloproteinase domain-containing protein 20 plays a crucial role in reproductive biology, potentially influencing sperm maturation and fertilization processes. Its unique enzymatic and binding capabilities suggest a multifunctional role in cellular interactions and molecular signaling pathways.
Therapeutic significance:
Understanding the role of Disintegrin and metalloproteinase domain-containing protein 20 could open doors to potential therapeutic strategies.